Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
Malignant mesothelioma (MM) is an aggressive malignancy of the serosal membranes. Early diagnosis and accurate prognostication remain problematic. BAP1 is a tumour suppressor gene commonly mutated in MM. Germline BAP1 mutation has been associated with early onset and less aggressive disease compared...
Main Authors: | Emily Pulford, Kalyani Huilgol, David Moffat, Douglas W. Henderson, Sonja Klebe |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2017-01-01
|
Series: | Disease Markers |
Online Access: | http://dx.doi.org/10.1155/2017/1310478 |
Similar Items
-
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
by: Carbone Michele, et al.
Published: (2012-08-01) -
BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
by: Alice Guazzelli, et al.
Published: (2019-01-01) -
BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
by: Raunak Shrestha, et al.
Published: (2019-02-01) -
Elucidating BAP1-microRNA regulatory networks in mesothelioma
by: Butt, Z.
Published: (2018) -
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
by: Marc Ladanyi, et al.
Published: (2019-03-01)